Pneumococcal vaccination responses in adults with subnormal IgG subclass concentrations.
IgG subclasses
Pneumococcal
Pneumovax®23
Primary immunodeficiency
Vaccine response
Journal
BMC immunology
ISSN: 1471-2172
Titre abrégé: BMC Immunol
Pays: England
ID NLM: 100966980
Informations de publication
Date de publication:
20 08 2019
20 08 2019
Historique:
received:
19
07
2018
accepted:
31
07
2019
entrez:
21
8
2019
pubmed:
21
8
2019
medline:
26
2
2020
Statut:
epublish
Résumé
We sought to compare Pneumovax®23 responses in adults with subnormal IgG subclass concentrations. We studied adults with normal total IgG, frequent/severe respiratory infection, and subnormal IgG1, IgG3, or IgG1 + IgG3 before and after Pneumovax®23. We defined response as serotype-specific IgG > 1.3 μg/mL and aggregate response as IgG > 1.3 μg/mL for ≥70% of all serotypes tested. We compared patients with and without serotype-specific responses and performed logistic regression on aggregate responses using: age; male sex; body mass index; autoimmune condition(s); atopy; other allergies; subnormal IgGSc immunophenotypes; IgA; and IgM. There were 59 patients (mean age 44 ± 13 (SD) years; 83.1% women). Median days between pre- and post-Pneumovax®23 testing was 33 (range 19-158). The median post-vaccination summated concentration of serotype-specific IgG was higher in patients with subnormal IgG1 than subnormal IgG3 (responders and non-responders). All subnormal IgG1 + IgG3 non-responders responded to serotypes 8, 9 and 26, unlike other non-responders. Subnormal IgG3 responders had lower responses to serotypes 1, 4, 12, 23, 26, and 51. Subnormal IgG3 non-responders had higher responses to serotypes 1, 3, 8, 9, 12, 14, 19, 51, and 56. Response rates decreased with increasing age. Aggregate responders were: subnormal IgG1, 54%; IgG3, 46%; and IgG1 + IgG3, 46%. Regression on aggregate response revealed lower response with male sex (odds ratio 0.09 [95% CI 0.01, 0.77]) and atopy (0.17 [0.03, 0.83]). Serotype-specific IgG responses to Pneumovax®23 were greater in patients with subnormal IgG1 than subnormal IgG3. Male sex and atopy were associated with lower aggregate responses.
Sections du résumé
BACKGROUND
We sought to compare Pneumovax®23 responses in adults with subnormal IgG subclass concentrations. We studied adults with normal total IgG, frequent/severe respiratory infection, and subnormal IgG1, IgG3, or IgG1 + IgG3 before and after Pneumovax®23. We defined response as serotype-specific IgG > 1.3 μg/mL and aggregate response as IgG > 1.3 μg/mL for ≥70% of all serotypes tested. We compared patients with and without serotype-specific responses and performed logistic regression on aggregate responses using: age; male sex; body mass index; autoimmune condition(s); atopy; other allergies; subnormal IgGSc immunophenotypes; IgA; and IgM.
RESULTS
There were 59 patients (mean age 44 ± 13 (SD) years; 83.1% women). Median days between pre- and post-Pneumovax®23 testing was 33 (range 19-158). The median post-vaccination summated concentration of serotype-specific IgG was higher in patients with subnormal IgG1 than subnormal IgG3 (responders and non-responders). All subnormal IgG1 + IgG3 non-responders responded to serotypes 8, 9 and 26, unlike other non-responders. Subnormal IgG3 responders had lower responses to serotypes 1, 4, 12, 23, 26, and 51. Subnormal IgG3 non-responders had higher responses to serotypes 1, 3, 8, 9, 12, 14, 19, 51, and 56. Response rates decreased with increasing age. Aggregate responders were: subnormal IgG1, 54%; IgG3, 46%; and IgG1 + IgG3, 46%. Regression on aggregate response revealed lower response with male sex (odds ratio 0.09 [95% CI 0.01, 0.77]) and atopy (0.17 [0.03, 0.83]).
CONCLUSIONS
Serotype-specific IgG responses to Pneumovax®23 were greater in patients with subnormal IgG1 than subnormal IgG3. Male sex and atopy were associated with lower aggregate responses.
Identifiants
pubmed: 31429700
doi: 10.1186/s12865-019-0310-3
pii: 10.1186/s12865-019-0310-3
pmc: PMC6701150
doi:
Substances chimiques
23-valent pneumococcal capsular polysaccharide vaccine
0
Antibodies, Bacterial
0
Immunoglobulin G
0
Pneumococcal Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
29Références
Clin Exp Immunol. 2000 Sep;121(3):448-52
pubmed: 10973715
Pediatr Infect Dis J. 1990 Aug;9(8 Suppl):S16-24
pubmed: 2216603
Clin Infect Dis. 1999 Aug;29(2):281-8
pubmed: 10476727
Monogr Allergy. 1986;20:106-15
pubmed: 3773900
Clin Immunol. 1999 Nov;93(2):132-42
pubmed: 10527689
Ann Rheum Dis. 1969 Mar;28(2):104-20
pubmed: 4180579
Vaccine. 2014 May 1;32(21):2399-405
pubmed: 24637174
J Allergy Clin Immunol. 2001 Apr;107(4):595-601
pubmed: 11295645
Scand J Immunol. 1990 Jun;31(6):711-6
pubmed: 2356437
J Korean Med Sci. 2013 Jan;28(1):4-15
pubmed: 23341706
J Infect Dis. 1996 Feb;173(2):387-93
pubmed: 8568300
BMC Med Genet. 2003 Jun 12;4:3
pubmed: 12803653
Respir Med. 2007 Sep;101(9):1845-63
pubmed: 17544265
PLoS One. 2015 Apr 22;10(4):e0123584
pubmed: 25901797
Cell Immunol. 2016 Jan;299:50-7
pubmed: 26410396
Vaccine. 2019 Feb 28;37(10):1350-1355
pubmed: 30737041
MMWR Morb Mortal Wkly Rep. 2014 Sep 19;63(37):822-5
pubmed: 25233284
J Clin Immunol. 2018 Jan;38(1):129-143
pubmed: 29226301
Clin Diagn Lab Immunol. 2004 Nov;11(6):1158-64
pubmed: 15539522
Clin Exp Immunol. 2014 Jul;177(1):272-9
pubmed: 24547957
J Infect Dis. 1985 May;151(5):845-9
pubmed: 3989318
J Immunoassay Immunochem. 2017;38(5):514-522
pubmed: 28613137
J Allergy Clin Immunol. 2015 Nov;136(5):1186-205.e1-78
pubmed: 26371839
J Immunol Res. 2016;2016:1405950
pubmed: 27123464
Ann Allergy Asthma Immunol. 2005 May;94(5 Suppl 1):S1-63
pubmed: 15945566
J Allergy Clin Immunol. 2009 Jan;123(1):195-200
pubmed: 18951616
Allergol Immunopathol (Madr). 2005 Mar-Apr;33(2):69-73
pubmed: 15808112
J Allergy Clin Immunol. 1993 Aug;92(2):353-5
pubmed: 8349944
Infect Immun. 1999 Sep;67(9):4935-8
pubmed: 10456954
Pediatr Pulmonol. 1996 Sep;22(3):167-73
pubmed: 8893255
Eur Arch Otorhinolaryngol. 1999;256(9):445-9
pubmed: 10552223
Diabetes Care. 2013 Jan;36 Suppl 1:S67-74
pubmed: 23264425
Clin Exp Immunol. 2004 Aug;137(2):366-72
pubmed: 15270854
Infect Immun. 2011 Jan;79(1):314-20
pubmed: 21041499
Clin Exp Immunol. 1983 Mar;51(3):600-4
pubmed: 6189654
Nature. 1967 Jun 17;214(5094):1224-5
pubmed: 4169229
Infect Immun. 2005 Nov;73(11):7465-76
pubmed: 16239548
Clin Exp Allergy. 2009 Apr;39(4):469-77
pubmed: 19222496
Genet Mol Res. 2015 Dec 08;14(4):16146-50
pubmed: 26662406
Clin Immunol Immunopathol. 1987 Dec;45(3):461-70
pubmed: 2445511
Clin Exp Immunol. 1990 Sep;81(3):357-67
pubmed: 2204502
Ann Trop Med Parasitol. 2010 Sep;104(6):455-64
pubmed: 20863434
Clin Infect Dis. 2010 Sep 15;51(6):692-9
pubmed: 20715907
Vaccine. 2004 Dec 21;23(6):762-8
pubmed: 15542200
Allergol Immunopathol (Madr). 1992 Jan-Feb;20(1):28-34
pubmed: 1509985
J Gerontol. 1987 May;42(3):265-70
pubmed: 3571861
Clin Immunol Immunopathol. 1997 Aug;84(2):194-201
pubmed: 9245552
N Engl J Med. 1980 Jul 24;303(4):178-82
pubmed: 6966763
J Korean Med Sci. 2010 Jun;25(6):824-8
pubmed: 20514300
MAbs. 2009 Jul-Aug;1(4):332-8
pubmed: 20073133
J Immunol Res. 2014;2014:542706
pubmed: 25295286
Clin Exp Immunol. 2010 Mar;159(3):344-50
pubmed: 20015274
J Clin Immunol. 2018 Jan;38(1):96-128
pubmed: 29226302
Nucleic Acids Res. 2005 Jan 1;33(Database issue):D256-61
pubmed: 15608191
C R Acad Sci III. 1999 Nov;322(11):925-32
pubmed: 10646085
Int Arch Allergy Appl Immunol. 1987;82(3-4):476-80
pubmed: 3570516
Clin Exp Immunol. 1986 Jan;63(1):127-34
pubmed: 3955880
Medicine (Baltimore). 2016 Sep;95(37):e4854
pubmed: 27631247
Clin Exp Immunol. 1989 Feb;75(2):201-5
pubmed: 2702775
Curr Opin Pediatr. 1993 Dec;5(6):696-9
pubmed: 8124421